Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 18, 2025Acta OncologicaOpen Access

Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJair BarMCMona H. CaiYCYookyung Christy Choi

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals c-Met overexpression impacts prognosis in non-small cell lung cancer, suggesting biomarker potential.

Key Points

  • This analysis aims to characterize c-Met protein overexpression and its prognostic significance in non-small cell lung cancer.
  • Retrospective analysis of tumor samples and clinical data from real-world patients with non-squamous NSCLC.
  • Patients selected based on available remnant tissue for biomarker analyses including c-Met immunohistochemistry.
  • Comparative assessments of c-Met protein expression, MET gene amplification, mRNA expression, and PD-L1 expression levels.
  • c-Met protein overexpression was detected in 25% of tissue samples.
  • MET gene amplification was identified in 9% of 212 samples with fluorescence in situ hybridization.
  • c-Met protein overexpression was linked to poor prognosis with a hazard ratio for death of 2.04.

Cite This Study

Bar et al. (2025) studied this question.

synapsesocial.com/papers/6924fef9c0ce034ddc351f95https://doi.org/10.2340/1651-226x.2025.44344
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer2025
  2. 2Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer2026
  3. 3MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer2025
  4. 4MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer2025
  5. 5Clinical significance of c-Met expression in patients with advanced gastroesophageal adenocarcinoma.2026